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Abstract. Mangiferin is a polyphenolic compound present 
in Salacia reticulata. It has been reported to reduce bone 
destruction and inhibit osteoclastic differentiation. This 
study aimed to determine whether mangiferin directly 
affects osteoblast and osteoclast proliferation and differen-
tiation, and gene expression in MC3T3-E1 osteoblastic cells 
and osteoclast-like cells derived from primary mouse bone 
marrow macrophage cells. Mangiferin induced significantly 
greater WST-1 activity, indicating increased cell prolif-
eration. Mangiferin induced significantly increased alkaline 
phosphatase staining, indicating greater cell differentiation. 
Reverse transcription-polymerase chain reaction (RT-PCR) 
demonstrated that mangiferin significantly increased the 
mRNA level of runt-related transcription factor 2 (RunX2), 
but did not affect RunX1 mRNA expression. Mangiferin 
significantly reduced the formation of tartrate‑resistant acid 
phosphatase-positive multinuclear cells. RT-PCR demon-
strated that mangiferin significantly increased the mRNA level 
of estrogen receptor β (ERβ), but did not affect the expres-
sion of other osteoclast-associated genes. Mangiferin may 
inhibit osteoclastic bone resorption by suppressing differentia-
tion of osteoclasts and promoting expression of ERβ mRNA 
in mouse bone marrow macrophage cells. It also has potential 
to promote osteoblastic bone formation by promoting cell 
proliferation and inducing cell differentiation in preosteoblast 
MC3T3-E1 cells via RunX2. Mangiferin may therefore be 
useful in improving bone disease outcomes.
Introduction
Mangiferin (MGF) is a naturally occurring polyphenolic 
compound commonly present in Mangifera indica and 
Salacia reticulata (1,2). MGF has a variety of pharmacological 
effects, including antiviral and an antioxidant activity (3,4). 
There have been a number of studies that have used MGF and 
S. reticulata for the treatment of diabetes mellitus; MGF and 
S. reticulata reportedly inhibit the activity of α-glucosidase 
and suppress the mRNA expression of fructose-1,6-bisphos-
phatase and glucose-6-phosphatase (5,6). The effects of MGF 
and S. reticulata on bone and cartilage disease have also 
been reported; S. reticulata leaf ameliorated the symptoms 
of rheumatoid arthritis (RA) by reducing bone tissue destruc-
tion in type II collagen antibody-induced arthritic mice (7). 
Furthermore, a previous study reported that MGF inhibits 
osteoclastic differentiation of RAW 264.7 cells (8).
Osteoblasts and osteoclasts have critical roles in bone 
tissue; bone metabolism is maintained by the balance of bone 
formation by osteoblasts and bone resorption by osteoclasts. 
Osteoblast- and osteoclast-associated bone diseases include 
osteoporosis, osteopetrosis and RA (9-11). RA is also a chronic 
inflammatory disease, characterized by inflammatory cell 
infiltration, synovial hyperplasia, and destruction of cartilage 
and bone (12-14); this bone tissue destruction is induced and 
promoted by osteoclast activation (15). In addition, osteoblasts 
produce receptor activator nuclear factor-κB ligand (RANKL) 
as an osteoclast differentiation factor (16).
RA treatment is currently primarily based on the adminis-
tration of anti‑inflammatory drugs, immunosuppressive drugs 
and antibody medicines (17-19); calcium, steroids and bisphos-
phonates have also been used to treat the deconstruction of 
bone (20-22). In addition, bone resorption can be suppressed 
and bone formation can be enhanced by estrogen receptors, 
such as estrogen receptor-α (ERα) and ERβ (23).
It was previously reported that the leaf of S. reticulata 
ameliorated the symptoms of arthritis in a mouse model of RA, 
and suppressed cell proliferation and gene expression of matrix 
metalloproteinase 3, RANKL, cathepsin K and c-fos mRNA 
in murine synovial cells derived from mice with RA (8). This 
improvement in RA symptoms was potentially associated with 
the MGF contained in S. reticulata. The present study exam-
ined whether MGF directly affects osteoblast and osteoclast 
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proliferation and differentiation. It was aimed to investigate 
whether MGF affects cell proliferation, cell differentiation, 
and gene expression in cultured osteoblasts and osteoclasts.
Materials and methods
Ethics statement. The use of experimental animals was 
approved, and this study was performed in accordance with 
the National Institute of Health (NIH) Guide for the Care and 
Use of Laboratory Animals and the Institutional Animal Care 
and Use Committee of Josai University (permit no. H22064; 
Saitama, Japan).
Cell and culture conditions. MC3T3-E1 cells were purchased 
from RIKEN Cell Bank (RIKEN BioResource Center, 
Tsukuba, Japan). The cells were cultured in α-minimal essen-
tial medium (MEM; Gibco; Thermo Fisher Scientific, Inc., 
Waltham, MA, USA) supplemented with 10% fetal bovine 
serum (Invitrogen; Thermo Fisher Scientific, Inc.) and peni-
cillin (50 IU/ml). Cells were subcultured every 2nd day using 
trypsin/EDTA (Sigma-Aldrich; Merck KGaA, Darmstadt, 
Germany), and were maintained at 37˚C in a humidified atmo-
sphere of 5% CO2 and 95% air.
Osteoclast-like cells (OCL) were derived from the bone 
marrow of three 8-week-old ddY male mice (Tokyo Laboratory 
Animals Science. Tokyo. Japan). Bone marrow macrophage 
(BMM) cells were prepared immediately from the femur and 
tibia of ddY mice. The BMM cells were induced by macro-
phage colony stimulating factor (M-CSF) from bone marrow 
cells. Cell suspensions were plated at 1x104 cells/well in a 
96-well plate in α-MEM containing 10% FBS, penicillin, and 
supplemented with M-CSF (20 ng/ml) and RANKL (10 ng/ml) 
to induce osteoclast differentiation. The cells were cultured as 
described previously (24).
Cell proliferation assay. MC3T3-E1 cells were plated in 
96-well microplates (BD Biosciences, Franklin Lakes, NJ, 
USA) at a density of 3x103 cells/well. After 24 h of incubation, 
MGF (1x10-3, 10-4, 10-5, 10-6 and 10-7 M) dissolved in dimethyl 
sulfoxide was mixed in the culture medium and added to each 
well. The control group was treated with medium only. After 
2 h, the cell proliferation reagent WST-1 (Roche Diagnostics, 
Indianapolis, IN, USA) was added to each well (1/10 volume of 
the previously added medium), and the plates were incubated 
for 30 min. Cell proliferation was then measured at 450 nm 
using a spectrophotometer (Wallac 1420ARVO.SX multilabel 
counter; PerkinElmer, Inc., Waltham, MA, USA). All experi-
ments were performed in triplicate with independent samples.
Alkaline phosphatase (ALP) activity. After 21 days of treat-
ment with MGF, MC3T3-E1 cells were fixed with 100% 
methanol. The fixed cells were incubated in ALP staining solu-
tion for 20 min at 37˚C; the ALP staining solution consisted 
of 0.05 M AMP buffer at pH 9.8, 10 mM naphthol AS-BI 
phosphate (Sigma-Aldrich; Merck KGaA), and 1 mM fast 
red violet LB salt (Sigma-Aldrich; Merck KGaA). The ALP 
stained areas were then inspected using a light microscope 
(Penguin 600CL; Pixera Corporation, Tokyo, Japan). The ALP 
activity was quantified by densitometric analysis using ImageJ 
software (version 1.3; National Institutes of Health, Bethesda, 
MD, USA). All experiments were performed in triplicate with 
independent samples.
Tartrate‑resistant acid phosphatase (TRAP) activity. 
After 6 days of culture, the OCL were fixed with 100% 
methanol. The fixed cells were incubated in the presence of 
L (+)-tartrate buffer (0.335 mol/l, pH 4.9±0.1) with a TRAP kit 
(Sigma‑Aldrich; Merck KGaA) for 5 min at 37˚C. Following 
staining, TRAP stained areas were inspected using a light 
microscope (Penguin 600CL). TRAP-positive cells containing 
three or more nuclei were counted as multinuclear osteoclasts. 
The TRAP activity was quantified by densitometric analysis 
using ImageJ software. All experiments were performed in 
triplicate with independent samples.
RNA extraction and reverse transcription‑polymerase chain 
reaction (RT‑PCR). Total RNA from MC3T3-E1, BMM and 
OCL were extracted from the cultures using TRIzol reagent, 
and RNA was extracted according to the manufacturer's 
protocol (Invitrogen; Thermo Fisher Scientific, Inc.). cDNA 
was prepared from 1 µg total RNA using the SuperScript 
First-Strand Synthesis system for RT-PCR (Invitrogen; Thermo 
Fisher Scientific, Inc.). Amplification was performed in 10 µl of 
reaction mixture containing 1 µl cDNA using EX Taq (Takara 
Bio, Inc., Otsu, Japan). The primer sequences used for each 
PCR are outlined below. Initial denaturation was performed at 
94˚C for 30 sec, annealing temperatures ranged from 58‑62˚C 
for 30 sec, and extension was done at 72˚C for 3 min. A final 
extension was performed at 72˚C for 3 min. PCR cycles varied 
from 20-60 cycles, due to certain genes, particularly RANK 
and cathepsin K, exhibiting multiple variations and therefore 
requiring further cycles in order to confirm gene expression.
Primers were as follows: Cathepsin K, 5'-CCA GTG TGG 
TTC CTG TTGG-3' (forward) and 5'-TTG CCG TGG CGT 
TAT ACAT-3' (reverse); ERα, 5'-AAT TCT GAC AAT CGA 
CGC CAG-3' (forward) and 5'-GTG CTT CAA CAT TCT CCC 
TCC TC-3' (reverse); ERβ, 5'-CAA GCT CAT CTT TGC TCC 
AG-3' (forward) and 5'-GCAGATGTTCCATGCCCTTG-3' 
(reverse); nuclear factor of activated T-cells, cytoplasmic 1 
(NFATc1), 5'-CAC CAA AGT CCT GGA GAT CC-3' (forward) 
and 5'-GAA ACG CTG GTA CTG GCT TC-3' (reverse); NF-κB, 
5'-GCT TTG CAA ACC TGG GAA TA-3' (forward) and 5'-TCC 
GCC TTC TGC TTG TAG AT-3' (reverse); RANK, 5'-CCA 
GGG GAC AAC GGA ATCAG-3' (forward) and 5'-GGC CGG 
TCC GTG TAC TCA TC-3' (reverse); osteoclast-associated 
receptor (OSCAR), 5'-TGT TCT GGA ACT GCT GGT AACG-3' 
(forward) and 5'-GAT GAG GTT TCC CTG GGT ATAG-3' 
(reverse); runt-related transcription factor 1 (RunX1), 5'-GGT 
CGT TGA ATC TCG CTA CC-3' (forward) and 5'-ACT TCC 
TCT GCT CCG TGC TA-3' (reverse); RunX2, 5'-ACA CCT ACT 
CTC ATA CTG GGA TGA GGA ATG-3' (forward) and 5'-ATG 
GTG GAG ATC ATC GCG GAC CAC CCG GCC-3' (reverse); 
GAPDH, 5'-TTG ACC TCA ACT ACA TGG-3' (forward) and 
5'-CAGGGTGGTGGACCTCAT-3' (reverse).
The PCR products were separated on 2% agarose gel 
with Tris-acetate-EDTA buffer and visualized with ethidium 
bromide. All gels were digitally imaged and the band inten-
sities of these digital images were determined using ImageJ 
software. Each mRNA level was normalized against the 
GAPDH mRNA level. All data are presented as the fold change 
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in the target/GAPDH ratio. All experiments were performed 
in triplicate with independent samples.
Statistical analysis. All experiments were performed with 
triplicate independent samples and were repeated at least three 
times, giving qualitatively identical results. Statistical analysis 
was carried out with Stat-Mate III version 3.18 (ATMS Co., 
Ltd., Tokyo, Japan). Data were analyzed using the Student's 
t‑test, with P<0.05 considered to indicate a statistically signifi-
cant difference.
Results
Effects of mangiferin on cell proliferation, cell differentiation 
and gene expression regulation of MC3T3‑E1 cells. In order 
to investigate the effect on cell proliferation, MGF was added 
at concentrations ranging from 10-3 M to 10-7 M. There was 
no change in cell proliferation with MGF at concentrations of 
10-4 M to 10-7 M compared with the control. Only 10-3 M MGF 
resulted in an increase in WST-1 activity; 10-3 M MGF induced 
>20% cell proliferation of MC 3T3-E1 cells compared with 
controls (Fig. 1A). Thus, 10-3 M MGF was selected for use in 
the subsequent experiments. In order to investigate the effect 
of MGF on cell differentiation, ALP staining was performed. 
MGF induced an ~2-fold increase in the ALP-stained area of 
MC 3T3-E1 cells compared with controls (Fig. 1B). Regarding 
the effect of MGF on the expression of genes involved in the 
differentiation of osteoblasts, MGF induced >2-fold increase 
in RunX2 mRNA expression in MC3T3-E1 cells; however, 
MGF did not affect the level of RunX1 mRNA expres-
sion (Fig. 2A and B).
Effects of mangiferin on cell differentiation and gene 
expression regulation in osteoclast lineage cells. The effect of 
10-3 M MGF on osteoclast differentiation was determined. The 
number of TRAP-positive multinuclear cells were counted. 
MGF reduced the number of TRAP-positive multinuclear cells 
by ~50% compared with the vehicle control (Fig. 3A and B). 
Regarding the effect of MGF on the expression of genes 
involved in the differentiation of osteoclasts, the cathepsin 
K and OSCAR mRNA expression in BMM cells was ~1/4 
of that in OCLs; RANK was two-fold higher and ERα was 
4-fold higher in BMM cells compared with mature OCL 
cells (Fig. 4A and 4B). In addition, MGF treatment increased 
the ERβ mRNA expression level in BMM by ~5-fold compared 
with untreated BMM. However, MGF did not affect the 
expression levels of cathepsin K, c-fos, ERα, NF-κB, NFATc1, 
OSCAR or RANK mRNA in BMM.
Figure 1. Effects of MGF on cell proliferation and differentiation of MC3T3-E1 
cells. (A) MC3T3-E1 cells were treated with or without MGF. After 2 h of 
incubation, cell proliferation was measured by WST-1. (B) MC3T3-E1 cells 
were treated with or without MGF. After 21 days of incubation, the cells were 
subjected to ALP staining. The results are expressed as the mean ± standard 
deviation of three independent experiments (n=3). *P<0.05. MGF, mangif-
erin; ALP, alkaline phosphatase.
Figure 2. Effect MGF on gene expression related to osteoblast-regulated 
genes. (A) Total RNA extracted from MC3T3-E1 cells treated with or 
without MGF (10-3 M) for 2 h. mRNA expression of RunX1 and RunX2 
were analyzed by reverse transcription-polymerase chain reaction. (B) The 
semi-quantitative results are expressed as the mean ± standard deviation of 
three independent experiments (n=3). *P<0.05. MGF, mangiferin; RunX, runt 
related transcription factor.
Figure 3. Effect of MGF on TRAP-positive MNCs formation from BMM 
cells. (A) Mouse BMM cells were treated with or without MGF (10-3 M) in 
the presence of macrophage colony stimulating factor (20 ng/ml) and receptor 
activator nuclear factor-κB ligand (10 ng/ml). TRAP staining was performed 
to determine the effect on osteoclast formation. After 6 days of incubation, 
the cells were subjected to TRAP staining and compared with osteoclast-like 
cells (control). (B) The results are expressed as the mean ± standard deviation 
of three independent experiments (n=3). Scale bar, 100 µm; original magni-
fication, x200. *P<0.05. MGF, mangiferin; TRAP, tartrate-resistant acid 
phosphatase; MNCs, multinuclear cells; BMM, bone marrow macrophage.
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Discussion
The present study aimed to investigate whether MGF affects 
cell proliferation, cell differentiation and gene expres-
sion in cultured osteoblasts and osteoclasts. For example, 
α-mangostin, a compound similar to MGF, has been reported 
to affect cell proliferation in human lung adenocarcinoma 
cells and human breast adenocarcinoma cells (25,26). The 
present study indicated that MGF may promote cell prolif-
eration and cell differentiation of osteoblasts. Furthermore, 
MGF may induce osteoblast differentiation from preosteo-
blasts to mature osteoblasts via RunX2. It is established that 
RunX1 regulates the differentiation of hematopoietic stem 
cells, and that RunX2 regulates the differentiation of osteo-
blasts (27,28). Additionally, Runx2 and ALP are validated 
osteoblastic differentiation markers (29-31). The results of the 
present study indicated that MGF may inhibit M-CSF- and 
RANKL-induced osteoclast formation and differentiation 
from BMM to TRAP-positive multinuclear cells as osteo-
clasts. These results indicate that MGF suppressed the 
differentiation of osteoclasts from BMM and promoted the 
expression of ERβ mRNA in BMM. These data suggest that 
MGF ay suppress osteoclastogenesis via the ERβ signal. 
In conventional investigation of osteoclasts, the effect on 
TRAP-positive cells indicates the induction of differentiation 
of osteoclasts (32,33). In addition, it is established that ER 
suppresses osteoclastogenesis (34,35).
In conclusion, MGF promoted cell proliferation and 
induced cell differentiation in preosteoblast MC3T3-E1 cells 
via RunX2; thus, MGF may potentially promote osteoblastic 
bone formation. MGF suppressed cell differentiation to 
mature OCL, and promoted the mRNA expression of ERβ in 
BMM; thus, MGF may potentially inhibit osteoclastic bone 
resorption. MGF may adjust the balance between osteoblast 
and osteoclast function, and could be useful in improving bone 
diseases. Further study is warranted into the use of MGF as a 
treatment for bone diseases such as osteoporosis, osteopetrosis 
and RA.
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